A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation.
Improving outcomes in severe paediatric asthma: New treatments, new possibilities
After watching this activity, participants should be better able to:
- Recall the symptoms associated with severe asthma in children
- Summarize the clinical evidence supporting the use of biologics in children with severe asthma
- Describe the optimal long-term management of children with severe asthma
In this activity, an asthma specialist and a primary care respiratory specialist respond to questions from healthcare professionals involved in the care of paediatric patients with severe asthma. They discuss the symptoms and diagnosis of childhood asthma, the latest data and rationale for the use of biologics in children, and the long-term management of these patients.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of allergists, immunologists, paediatricians, pulmonologists and general practice physicians involved in the management of paediatric patients with severe paediatric asthma.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Leonard Bacharier discloses: Advisory board/Panel fees from AstraZeneca (relationship terminated), GlaxoSmithKline (relationship terminated), Regeneron Pharmaceuticals, Sanofi and Vertex Pharmaceuticals. Consultancy fees from OMPharma. Speaker’s bureau Fees from Regeneron Pharmaceuticals.
Dr Dermot Ryan discloses: Consultant fees from Regeneron Pharmaceuticals (relationship terminated) and Thermo Fisher Scientific. Speaker’s bureau fees from Glenmark Pharmaceuticals and Viatris (relationship terminated).
Karim Hanna, MD has no relevant financial relationships to disclose.
Touch Medical Director
Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 15 December 2022. Dates credits expire: 15 December 2023.
If you have any questions regarding credit please contact firstname.lastname@example.org
To obtain the CME credit(s) from this activity, please complete this post-activity test.Claim Credit
You may also be interested in...
Luis Felipe C. Ensina, AAAAI 2023: Ligelizumab for the treatment of chronic spontaneous urticaria – findings from PEARL-1 and PEARL-2
The practicalities of eosinophilic oesophagitis management: A closer look at emerging biologic treatment optionsThis activity is CE/CME accredited
Improving outcomes for patients with eosinophilic oesophagitis: What do the data from AAAAI 2022 tell us?This activity is CE/CME accredited
Vasileios Kouranos, ERS 2020 – Management of Cardiac Sarcoidosis
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 8 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!